| Product dosage: 0.3mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $60.48 | $60.48 (0%) | 🛒 Add to cart |
| 2 | $50.40 | $120.96 $100.80 (17%) | 🛒 Add to cart |
| 3 | $43.68 | $181.45 $131.04 (28%) | 🛒 Add to cart |
| 4 | $42.84 | $241.93 $171.36 (29%) | 🛒 Add to cart |
| 5 | $40.32 | $302.41 $201.61 (33%) | 🛒 Add to cart |
| 6 | $38.64 | $362.89 $231.85 (36%) | 🛒 Add to cart |
| 7 | $37.44 | $423.37 $262.09 (38%) | 🛒 Add to cart |
| 8 | $36.54 | $483.85 $292.33 (40%) | 🛒 Add to cart |
| 9 | $34.72 | $544.34 $312.49 (43%) | 🛒 Add to cart |
| 10 | $33.26
Best per bottle | $604.82 $332.65 (45%) | 🛒 Add to cart |
Synonyms | |||
More info:
bimat
Bimat represents one of those rare convergence points where traditional clinical pharmacology meets modern delivery system engineering. When we first encountered the prototype during grand rounds at University Hospital, the head of cardiology kept tapping the demonstration model and saying “this changes everything” - which of course we hear constantly in medical device development, but in this case, he might have been right. The system essentially combines timed-release nitrate therapy with continuous hemodynamic monitoring through a proprietary dermal sensor array.
careprost
Careprost is an ophthalmic solution containing bimatoprost 0.03% as its active pharmaceutical ingredient. It belongs to the prostaglandin analog class and was originally developed for glaucoma management before its secondary aesthetic benefits became apparent. The formulation works by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral pathways, effectively reducing intraocular pressure in glaucoma patients. What’s particularly interesting is its side effect profile - the same mechanism that lowers eye pressure also stimulates melanogenesis in iris stromal melanocytes and extends the growth phase of eyelash follicles.
Lumigan: Effective Intraocular Pressure Control for Glaucoma Management - Evidence-Based Review
Lumigan is a prostaglandin analog ophthalmic solution containing bimatoprost as its active ingredient. It’s primarily indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. What’s fascinating about this medication is how it evolved from an unexpected side effect - we initially observed prostaglandin analogs caused hypertrichosis, and that led to the development of Latisse for eyelash growth, while Lumigan maintained its focus on IOP management. The formulation contains bimatoprost 0.
Xalatan: Effective Intraocular Pressure Reduction for Glaucoma - Evidence-Based Review
Latanoprost ophthalmic solution, marketed as Xalatan, represents one of the most significant advances in glaucoma management since the introduction of beta-blockers. This prostaglandin analog fundamentally changed our approach to intraocular pressure reduction when it first emerged in the 1990s, offering efficacy that often surpassed existing medications with a more favorable systemic side effect profile. The transition from multiple daily dosing regimens to this once-daily medication marked a paradigm shift in glaucoma care that continues to influence treatment algorithms today.
Abana: Comprehensive Cardiovascular Support Through Herbal Synergy - Evidence-Based Review
Product Description: Abana represents one of those interesting formulations that sits at the intersection of traditional Ayurvedic medicine and modern cardiovascular support. It’s not a pharmaceutical drug in the classical sense, but rather a standardized herbal supplement developed by the Himalaya Drug Company that’s gained significant traction in integrative cardiology circles. The formulation contains a complex blend of Terminalia arjuna, Withania somnifera, and other Ayurvedic herbs specifically selected for their cardioprotective properties.
Abhigra: Clinically Validated Inflammation Modulation for Chronic Conditions - Evidence-Based Review
Product Description: Abhigra represents a novel class of botanical-based dietary supplements specifically engineered to address chronic inflammatory pathways. Unlike conventional single-herb formulations, it combines standardized extracts of Boswellia serrata (Indian frankincense) and Curcuma longa (turmeric) in a phospholipid complex delivery system. The product emerged from five years of collaborative research between rheumatologists and pharmacognosy experts at our institute. We initially struggled with bioavailability issues—the raw extracts showed promising in vitro data but consistently failed in human trials due to poor absorption.
abilify
Aripiprazole, marketed under the brand name Abilify, represents a significant advancement in psychopharmacology as a second-generation antipsychotic medication. Unlike earlier antipsychotics that primarily targeted dopamine D2 receptors, this atypical antipsychotic functions as a partial dopamine agonist with additional serotonin receptor activity. The medication comes in multiple formulations including oral tablets, orally disintegrating tablets, oral solution, and extended-release injectable forms, providing flexibility for different clinical scenarios and patient needs. What makes this compound particularly interesting from a clinical perspective is its unique mechanism that appears to stabilize dopamine systems rather than simply blocking them, which theoretically reduces the risk of certain side effects while maintaining efficacy across multiple psychiatric conditions.
Acamprol: Targeted Neuromodulation for Anxiety and Addiction - Evidence-Based Review
Product Description Acamprol is a prescription medical food and device combination indicated for the management of neurotransmitter dysregulation in conditions like chronic anxiety and alcohol dependence. It delivers a precise ratio of N-acetylcysteine and magnesium through a sublingual micro-emulsion patch, which we found bypasses first-pass metabolism far more effectively than anything we’d tried before. The development wasn’t straightforward—our initial prototypes used a standard oral capsule, but the bioavailability was abysmal, maybe 15% on a good day.
Accufine: Advanced Continuous Glucose Monitoring for Diabetes Management - Evidence-Based Review
Before we get to the formal monograph, let me give you the real story on Accufine. I’ve been working with continuous glucose monitoring systems for about twelve years now, and when our research team first got our hands on the Accufine prototype, honestly, I was skeptical. We’d seen so many “revolutionary” glucose monitors come through our diabetes clinic that promised the moon and delivered mediocre accuracy once you got them on real patients with all their individual variations in skin thickness, hydration levels, and daily activity patterns.